|
US3691016A
(en)
|
1970-04-17 |
1972-09-12 |
Monsanto Co |
Process for the preparation of insoluble enzymes
|
|
CA1023287A
(en)
|
1972-12-08 |
1977-12-27 |
Boehringer Mannheim G.M.B.H. |
Process for the preparation of carrier-bound proteins
|
|
US4195128A
(en)
|
1976-05-03 |
1980-03-25 |
Bayer Aktiengesellschaft |
Polymeric carrier bound ligands
|
|
US4330440A
(en)
|
1977-02-08 |
1982-05-18 |
Development Finance Corporation Of New Zealand |
Activated matrix and method of activation
|
|
CA1093991A
(en)
|
1977-02-17 |
1981-01-20 |
Hideo Hirohara |
Enzyme immobilization with pullulan gel
|
|
US4229537A
(en)
|
1978-02-09 |
1980-10-21 |
New York University |
Preparation of trichloro-s-triazine activated supports for coupling ligands
|
|
US4543439A
(en)
|
1982-12-13 |
1985-09-24 |
Massachusetts Institute Of Technology |
Production and use of monoclonal antibodies to phosphotyrosine-containing proteins
|
|
IL71691A
(en)
|
1984-04-27 |
1991-04-15 |
Yeda Res & Dev |
Production of interferon-ypsilon
|
|
US5139941A
(en)
|
1985-10-31 |
1992-08-18 |
University Of Florida Research Foundation, Inc. |
AAV transduction vectors
|
|
US5474982A
(en)
|
1986-08-13 |
1995-12-12 |
Zymogenetics, Inc. |
PDGF analogs and methods of use
|
|
US5322691A
(en)
|
1986-10-02 |
1994-06-21 |
Sohrab Darougar |
Ocular insert with anchoring protrusions
|
|
JP2736255B2
(ja)
|
1987-03-11 |
1998-04-02 |
フアルマシア・エ・アツプジヨン・エツセ・ピー・アー |
イムノグロブリン結合体
|
|
US6018026A
(en)
|
1988-01-22 |
2000-01-25 |
Zymogenetics, Inc. |
Biologically active dimerized and multimerized polypeptide fusions
|
|
US5750375A
(en)
|
1988-01-22 |
1998-05-12 |
Zymogenetics, Inc. |
Methods of producing secreted receptor analogs and biologically active dimerized polypeptide fusions
|
|
DE68926888T2
(de)
|
1988-01-22 |
1997-01-09 |
Zymogenetics Inc |
Verfahren zur Herstellung von sekretierten Rezeptoranalogen
|
|
GB8823869D0
(en)
|
1988-10-12 |
1988-11-16 |
Medical Res Council |
Production of antibodies
|
|
US5530101A
(en)
|
1988-12-28 |
1996-06-25 |
Protein Design Labs, Inc. |
Humanized immunoglobulins
|
|
WO1990014425A1
(en)
|
1989-05-22 |
1990-11-29 |
Zymogenetics, Inc. |
PDGF α-RECEPTOR
|
|
US5585362A
(en)
|
1989-08-22 |
1996-12-17 |
The Regents Of The University Of Michigan |
Adenovirus vectors for gene therapy
|
|
US5183884A
(en)
|
1989-12-01 |
1993-02-02 |
United States Of America |
Dna segment encoding a gene for a receptor related to the epidermal growth factor receptor
|
|
US5670488A
(en)
|
1992-12-03 |
1997-09-23 |
Genzyme Corporation |
Adenovirus vector for gene therapy
|
|
WO1991018088A1
(en)
|
1990-05-23 |
1991-11-28 |
The United States Of America, Represented By The Secretary, United States Department Of Commerce |
Adeno-associated virus (aav)-based eucaryotic vectors
|
|
US6011020A
(en)
|
1990-06-11 |
2000-01-04 |
Nexstar Pharmaceuticals, Inc. |
Nucleic acid ligand complexes
|
|
US6147204A
(en)
|
1990-06-11 |
2000-11-14 |
Nexstar Pharmaceuticals, Inc. |
Nucleic acid ligand complexes
|
|
US5633425A
(en)
|
1990-08-29 |
1997-05-27 |
Genpharm International, Inc. |
Transgenic non-human animals capable of producing heterologous antibodies
|
|
US5625126A
(en)
|
1990-08-29 |
1997-04-29 |
Genpharm International, Inc. |
Transgenic non-human animals for producing heterologous antibodies
|
|
US5545806A
(en)
|
1990-08-29 |
1996-08-13 |
Genpharm International, Inc. |
Ransgenic non-human animals for producing heterologous antibodies
|
|
ATE158021T1
(de)
|
1990-08-29 |
1997-09-15 |
Genpharm Int |
Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper
|
|
US5661016A
(en)
|
1990-08-29 |
1997-08-26 |
Genpharm International Inc. |
Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
|
|
US5328688A
(en)
|
1990-09-10 |
1994-07-12 |
Arch Development Corporation |
Recombinant herpes simplex viruses vaccines and methods
|
|
US5849571A
(en)
|
1990-10-10 |
1998-12-15 |
University Of Pittsburgh Of The Commonwealth System Of Higher Education |
Latency active herpes virus promoters and their use
|
|
GB9101645D0
(en)
|
1991-01-25 |
1991-03-06 |
British Bio Technology |
Compounds
|
|
DK0584082T3
(da)
|
1991-01-31 |
2000-10-16 |
Univ California |
Domæner i den ekstracellulære region af humane blodpladeafledte vækstfaktorreceptorpolypeptider
|
|
US5840867A
(en)
|
1991-02-21 |
1998-11-24 |
Gilead Sciences, Inc. |
Aptamer analogs specific for biomolecules
|
|
DE69232718T2
(de)
|
1991-02-22 |
2003-04-03 |
American Cyanamid Co., Madison |
Identifizierung eines menschlichen rezeptor-tyrosinkinasegens
|
|
US5231001A
(en)
|
1991-03-14 |
1993-07-27 |
The United States Of America As Represented By The Department Of Health And Human Services |
Trk tyrosine kinase receptor is the physiological receptor for nerve growth factor
|
|
US5270458A
(en)
|
1991-04-02 |
1993-12-14 |
The Trustees Of Princeton University |
Nucleic acids encoding fragments of hematopoietic stem cell receptor flk-2
|
|
US5367057A
(en)
|
1991-04-02 |
1994-11-22 |
The Trustees Of Princeton University |
Tyrosine kinase receptor flk-2 and fragments thereof
|
|
US5185438A
(en)
|
1991-04-02 |
1993-02-09 |
The Trustees Of Princeton University |
Nucleic acids encoding hencatoporetic stem cell receptor flk-2
|
|
US5582981A
(en)
|
1991-08-14 |
1996-12-10 |
Gilead Sciences, Inc. |
Method for identifying an oligonucleotide aptamer specific for a target
|
|
AU669124B2
(en)
|
1991-09-18 |
1996-05-30 |
Kyowa Hakko Kirin Co., Ltd. |
Process for producing humanized chimera antibody
|
|
US5252479A
(en)
|
1991-11-08 |
1993-10-12 |
Research Corporation Technologies, Inc. |
Safe vector for gene therapy
|
|
EP0620826A1
(en)
|
1992-01-09 |
1994-10-26 |
Helsinki University Holding, Ltd. |
Tie, a novel endothelial cell receptor tyrosine kinase
|
|
US6331302B1
(en)
|
1992-01-22 |
2001-12-18 |
Genentech, Inc. |
Protein tyrosine kinase agonist antibodies
|
|
AU3482493A
(en)
|
1992-01-22 |
1993-09-01 |
New England Deaconess Hospital |
Novel protein tyrosine kinases
|
|
US5635177A
(en)
|
1992-01-22 |
1997-06-03 |
Genentech, Inc. |
Protein tyrosine kinase agonist antibodies
|
|
FR2686899B1
(fr)
|
1992-01-31 |
1995-09-01 |
Rhone Poulenc Rorer Sa |
Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
|
|
US5776427A
(en)
|
1992-03-05 |
1998-07-07 |
Board Of Regents, The University Of Texas System |
Methods for targeting the vasculature of solid tumors
|
|
US5234784A
(en)
|
1992-04-01 |
1993-08-10 |
Eastman Kodak Company |
Method of making a projection viewable transparency comprising an electrostatographic toner image
|
|
US5879934A
(en)
|
1992-07-31 |
1999-03-09 |
University Of Pittsburgh Of The Commonwealth System Of Higher Education |
Herpes simplex virus strains for gene transfer
|
|
US6107046A
(en)
|
1992-10-09 |
2000-08-22 |
Orion Corporation |
Antibodies to Flt4, a receptor tyrosine kinase and uses thereof
|
|
US6824777B1
(en)
|
1992-10-09 |
2004-11-30 |
Licentia Ltd. |
Flt4 (VEGFR-3) as a target for tumor imaging and anti-tumor therapy
|
|
US5776755A
(en)
|
1992-10-09 |
1998-07-07 |
Helsinki University Licensing, Ltd. |
FLT4, a receptor tyrosine kinase
|
|
AU687727B2
(en)
|
1992-10-28 |
1998-03-05 |
Genentech Inc. |
Vascular endothelial cell growth factor antagonists
|
|
US5763441A
(en)
|
1992-11-13 |
1998-06-09 |
Sugen, Inc. |
Compounds for the treatment of disorders related to vasculogenesis and/or angiogenesis
|
|
US5712395A
(en)
|
1992-11-13 |
1998-01-27 |
Yissum Research Development Corp. |
Compounds for the treatment of disorders related to vasculogenesis and/or angiogenesis
|
|
US5661033A
(en)
|
1992-11-25 |
1997-08-26 |
The Board Of Trustees Of The Leland Stanford Junior University |
Gene transfer using herpes virus vectors as a tool for neuroprotection
|
|
US5631237A
(en)
|
1992-12-22 |
1997-05-20 |
Dzau; Victor J. |
Method for producing in vivo delivery of therapeutic agents via liposomes
|
|
DE4311651A1
(de)
|
1993-04-08 |
1994-10-13 |
Boehringer Ingelheim Int |
Virus für den Transport von Fremd-DNA in höhere eukaryotische Zellen
|
|
US5834441A
(en)
|
1993-09-13 |
1998-11-10 |
Rhone-Poulenc Rorer Pharmaceuticals Inc. |
Adeno-associated viral (AAV) liposomes and methods related thereto
|
|
WO1995013365A1
(en)
|
1993-11-09 |
1995-05-18 |
Targeted Genetics Corporation |
Generation of high titers of recombinant aav vectors
|
|
US5443505A
(en)
|
1993-11-15 |
1995-08-22 |
Oculex Pharmaceuticals, Inc. |
Biocompatible ocular implants
|
|
US5700823A
(en)
|
1994-01-07 |
1997-12-23 |
Sugen, Inc. |
Treatment of platelet derived growth factor related disorders such as cancers
|
|
FR2716682B1
(fr)
|
1994-01-28 |
1996-04-26 |
Centre Nat Rech Scient |
Procédé de préparation de virus adéno-associés (AAV) recombinants et utilisations.
|
|
US6448077B1
(en)
|
1994-02-10 |
2002-09-10 |
Imclone Systems, Inc. |
Chimeric and humanized monoclonal antibodies specific to VEGF receptors
|
|
EP0751992B1
(en)
|
1994-03-08 |
2005-11-09 |
Human Genome Sciences, Inc. |
Vascular endothelial growth factor 2
|
|
US6608182B1
(en)
|
1994-03-08 |
2003-08-19 |
Human Genome Sciences, Inc. |
Human vascular endothelial growth factor 2
|
|
US6734285B2
(en)
|
1994-03-08 |
2004-05-11 |
Human Genome Sciences, Inc. |
Vascular endothelial growth factor 2 proteins and compositions
|
|
US5932540A
(en)
|
1994-03-08 |
1999-08-03 |
Human Genome Sciences, Inc. |
Vascular endothelial growth factor 2
|
|
US6040157A
(en)
|
1994-03-08 |
2000-03-21 |
Human Genome Sciences, Inc. |
Vascular endothelial growth factor 2
|
|
GB9410534D0
(en)
|
1994-05-26 |
1994-07-13 |
Lynxvale Ltd |
Improvements in or relating to growth factor inhibitors
|
|
AU694524B2
(en)
|
1994-06-09 |
1998-07-23 |
Helsinki University Licensing Ltd Oy |
Flt4 receptor tyrosine kinase and its use in diagnosis and therapy
|
|
US6204059B1
(en)
|
1994-06-30 |
2001-03-20 |
University Of Pittsburgh |
AAV capsid vehicles for molecular transfer
|
|
US5763733A
(en)
|
1994-10-13 |
1998-06-09 |
Enzon, Inc. |
Antigen-binding fusion proteins
|
|
US5856152A
(en)
|
1994-10-28 |
1999-01-05 |
The Trustees Of The University Of Pennsylvania |
Hybrid adenovirus-AAV vector and methods of use therefor
|
|
WO1998033917A1
(en)
|
1994-11-14 |
1998-08-06 |
The Ludwig Institute For Cancer Research |
Vascular endothelial growth factor c (vegf-c) protein and gene, mutants thereof, and uses thereof
|
|
US6645933B1
(en)
|
1995-08-01 |
2003-11-11 |
Helsinki University Licensing Ltd. Oy |
Receptor ligand VEGF-C
|
|
US6130071A
(en)
|
1997-02-05 |
2000-10-10 |
Helsinki University Licensing, Ltd. |
Vascular endothelial growth factor C (VEGF-C) ΔCys156 protein and gene, and uses thereof
|
|
US6221839B1
(en)
|
1994-11-14 |
2001-04-24 |
Helsinki University Licensing Ltd. Oy |
FIt4 ligand and methods of use
|
|
US6403088B1
(en)
|
1995-08-01 |
2002-06-11 |
Helsinki University Licensing, Ltd. |
Antibodies reactive with VEGF-C, a ligand for the Flt4 receptor tyrosine kinase (VEGFR-3)
|
|
US6245530B1
(en)
|
1995-08-01 |
2001-06-12 |
Ludwig Institute For Cancer Research |
Receptor ligand
|
|
US5792453A
(en)
|
1995-02-28 |
1998-08-11 |
The Regents Of The University Of California |
Gene transfer-mediated angiogenesis therapy
|
|
US5707618A
(en)
|
1995-03-24 |
1998-01-13 |
Genzyme Corporation |
Adenovirus vectors for gene therapy
|
|
IL117645A
(en)
|
1995-03-30 |
2005-08-31 |
Genentech Inc |
Vascular endothelial cell growth factor antagonists for use as medicaments in the treatment of age-related macular degeneration
|
|
FR2732357B1
(fr)
|
1995-03-31 |
1997-04-30 |
Rhone Poulenc Rorer Sa |
Vecteurs viraux et utilisation pour le traitement des desordres hyperproliferatifs, notamment de la restenose
|
|
US5869079A
(en)
|
1995-06-02 |
1999-02-09 |
Oculex Pharmaceuticals, Inc. |
Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents
|
|
US5773289A
(en)
|
1995-06-06 |
1998-06-30 |
University Of Pittsburgh |
AAV directed targeted integration
|
|
US6699843B2
(en)
|
1995-06-07 |
2004-03-02 |
Gilead Sciences, Inc. |
Method for treatment of tumors using nucleic acid ligands to PDGF
|
|
US6361946B1
(en)
|
1997-02-05 |
2002-03-26 |
Licentia Ltd |
Vascular endothelial growth factor C (VEGF-C) protein and gene, mutants thereof, and uses thereof
|
|
US5622856A
(en)
|
1995-08-03 |
1997-04-22 |
Avigen |
High efficiency helper system for AAV vector production
|
|
US5730977A
(en)
|
1995-08-21 |
1998-03-24 |
Mitsui Toatsu Chemicals, Inc. |
Anti-VEGF human monoclonal antibody
|
|
ES2202469T5
(es)
|
1995-09-08 |
2011-06-06 |
Genentech, Inc. |
Proteína relacionada con el vegf.
|
|
DE69638142D1
(de)
|
1995-09-29 |
2010-04-15 |
Univ Siena |
Regulierte Gene und ihre Verwendungen
|
|
US5830727A
(en)
|
1995-11-18 |
1998-11-03 |
Human Gene Therapy Research Institute |
Herpes simplex virus amplicon mini-vector gene transfer system
|
|
BR9707589A
(pt)
|
1996-02-20 |
2000-01-04 |
Applied Research Systems |
Proteìna hìbrida, molécula de dna, vetor de expressão, célula hospedeira, composição farmacêutica e processos para produzir proteìna hìbrida e para induzir maturação folicular.
|
|
US6100071A
(en)
|
1996-05-07 |
2000-08-08 |
Genentech, Inc. |
Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production
|
|
CA2258721C
(en)
|
1996-07-12 |
2014-09-09 |
Genentech, Inc. |
Chimeric heteromultimer adhesins
|
|
WO1998002543A1
(fr)
|
1996-07-15 |
1998-01-22 |
Chugai Research Institute For Molecular Medicine, Inc. |
Nouveaux facteurs analogues au vegf
|
|
US6423512B1
(en)
|
1996-07-26 |
2002-07-23 |
Novartis Ag |
Fusion polypeptides
|
|
EP1283268A3
(en)
|
1996-08-23 |
2004-01-02 |
Ludwig Institute For Cancer Research |
Recombinant vascular endothelial cell growth factor D (VEGF-D)
|
|
ATE343400T1
(de)
|
1996-09-24 |
2006-11-15 |
Merck & Co Inc |
Verbindungen zur hemmung der angiogenese durch gentherapie
|
|
US6051698A
(en)
|
1997-06-06 |
2000-04-18 |
Janjic; Nebojsa |
Vascular endothelial growth factor (VEGF) nucleic acid ligand complexes
|
|
ZA9711456B
(en)
|
1996-12-20 |
1998-06-30 |
Ludwig Inst Cancer Res |
VEGF-B/receptor complex and uses thereof.
|
|
US7125714B2
(en)
|
1997-02-05 |
2006-10-24 |
Licentia Ltd. |
Progenitor cell materials and methods
|
|
KR100816621B1
(ko)
|
1997-04-07 |
2008-03-24 |
제넨테크, 인크. |
항-ｖｅｇｆ 항체
|
|
CA2315977A1
(en)
|
1997-12-24 |
1999-07-08 |
Ludwig Institute For Cancer Research |
Expression vectors and cell lines expressing vascular endothelial growth factor d, and method of treating melanomas
|
|
DE69933216T2
(de)
|
1998-06-15 |
2007-09-20 |
GTC Biotherapeutics, Inc., Framingham |
Erythropoietin-analog-menschliches serum-albumin fusionsprotein
|
|
US20020164687A1
(en)
|
1998-09-30 |
2002-11-07 |
Ulf Eriksson |
Platelet-derived growth factor C, DNA coding therefor, and uses thereof
|
|
ATE489108T1
(de)
|
1998-10-09 |
2010-12-15 |
Vegenics Ltd |
Flt4 (vegfr-3) als ziel für tumornachweis (imaging) und antitumortherapie
|
|
NZ511115A
(en)
|
1998-10-19 |
2005-01-28 |
Ludwig Inst Cancer Res |
A neuropilin and vascular endothelial growth factor (VEGF) complex and uses thereof in hibitng bioactiviy of growth factors in tumor cells
|
|
AU775956B2
(en)
|
1998-11-02 |
2004-08-19 |
Otago Innovation Limited |
Vascular endothelial growth factor-like protein from ORF virus NZ2 binds and activates mammalian VEGF receptor-2
|
|
US7148037B2
(en)
|
1998-11-10 |
2006-12-12 |
Ludwig Institute For Cancer Research |
Platelet-derived growth factor D, DNA coding therefor, and uses thereof
|
|
WO2000037025A2
(en)
|
1998-12-21 |
2000-06-29 |
Ludwig Institute For Cancer Research |
Antibodies to truncated vegf-d and uses thereof
|
|
JP2000191337A
(ja)
|
1998-12-25 |
2000-07-11 |
Furukawa Electric Co Ltd:The |
フ―ド付きガラス微粒子合成用ト―チ
|
|
US20020064528A1
(en)
|
2000-01-28 |
2002-05-30 |
Zhenping Zhu |
Antibodies specific to KDR and uses thereof
|
|
HK1042052A1
(zh)
|
1999-02-08 |
2002-08-02 |
Human Genome Sciences, Inc. |
内皮血管生长因子-2
|
|
US6342219B1
(en)
|
1999-04-28 |
2002-01-29 |
Board Of Regents, The University Of Texas System |
Antibody compositions for selectively inhibiting VEGF
|
|
BR0010750A
(pt)
|
1999-05-17 |
2002-02-26 |
Conjuchem Inc |
Peptìdeos insulinotrópicos de longa duração
|
|
CN101433715B
(zh)
|
1999-06-08 |
2013-04-17 |
里珍纳龙药品有限公司 |
具有改善的药物动力学特性的修饰嵌合多肽
|
|
US7087411B2
(en)
|
1999-06-08 |
2006-08-08 |
Regeneron Pharmaceuticals, Inc. |
Fusion protein capable of binding VEGF
|
|
CA2377513A1
(en)
|
1999-06-25 |
2001-01-04 |
Universitat Zurich |
Hetero-associating coiled-coil peptides
|
|
US7754855B1
(en)
|
1999-07-13 |
2010-07-13 |
Bolder Biotechnology, Inc. |
Immunoglobulin fusion proteins
|
|
WO2001012669A1
(en)
|
1999-08-16 |
2001-02-22 |
Universita' Degli Studi Di Siena |
Vegf-d and angiogenic use thereof
|
|
CA2383499C
(en)
|
1999-10-21 |
2009-11-24 |
Alcon Universal Ltd. |
Drug delivery device
|
|
WO2001052875A1
(en)
|
2000-01-18 |
2001-07-26 |
Ludwig Institute For Cancer Research |
Vegf-d/vegf-c/vegf peptidomimetic inhibitor
|
|
AU2001239884B2
(en)
|
2000-02-25 |
2006-08-10 |
Vegenics Limited |
Materials and methods involving hybrid vascular endothelial growth factor DNAs and proteins and screening methods for modulators
|
|
ATE284701T1
(de)
|
2000-03-02 |
2005-01-15 |
Ludwig Inst Cancer Res |
Methode zur behandlung von tumoren welche den vaskulären endothelialen wachstumsfaktor d exprimieren
|
|
US20020102260A1
(en)
|
2000-03-02 |
2002-08-01 |
Marc Achen |
Methods for treating neoplastic disease characterized by vascular endothelial growth factor D expression, for screening for neoplastic disease or metastatic risk, and for maintaining vascularization of tissue
|
|
AU2001264565B2
(en)
|
2000-05-03 |
2006-12-07 |
Vegenics Limited |
A method for activating only the vascular endothelial growth factor receptor-3 and uses thereof
|
|
JP2004505619A
(ja)
|
2000-08-04 |
2004-02-26 |
ヒューマン ジノーム サイエンシーズ， インコーポレイテッド |
血管内皮増殖因子２
|
|
US20020151489A1
(en)
|
2000-10-02 |
2002-10-17 |
St. Elizabeth's Medical Center Of Boston, Inc. |
Use of lymphangiogenic agents to treat lymphatic disorders
|
|
US20020197691A1
(en)
|
2001-04-30 |
2002-12-26 |
Myriad Genetics, Incorporated |
FLT4-interacting proteins and use thereof
|
|
US20030211988A1
(en)
|
2001-01-09 |
2003-11-13 |
Epstein Stephen E |
Enhancing lymph channel development and treatment of lymphatic obstructive disease
|
|
US7611711B2
(en)
|
2001-01-17 |
2009-11-03 |
Vegenics Limited |
VEGFR-3 inhibitor materials and methods
|
|
CA2435503C
(en)
|
2001-01-19 |
2011-02-22 |
Ludwig Institute For Cancer Research |
Flt4(vegfr-3) as a target for tumor imaging and anti-tumor therapy
|
|
JP2004536579A
(ja)
|
2001-04-13 |
2004-12-09 |
ヒューマン ジノーム サイエンシーズ， インコーポレイテッド |
血管内皮増殖因子２
|
|
AU2002256172A1
(en)
|
2001-04-13 |
2002-10-28 |
Human Genome Sciences, Inc. |
Vascular endothelial growth factor 2
|
|
AU2002252631A1
(en)
|
2001-04-13 |
2002-10-28 |
Human Genome Sciences, Inc. |
Vascular endothelial growth factor 2
|
|
AU2002323501C1
(en)
*
|
2001-08-30 |
2010-04-29 |
Biorexis Technology, Inc |
Modified transferrin fusion proteins
|
|
US20030180294A1
(en)
|
2002-02-22 |
2003-09-25 |
Devries Gerald W. |
Methods of extending corneal graft survival
|
|
EP2298346A3
(en)
|
2002-03-04 |
2011-11-16 |
Imclone LLC |
Human antibodies specific to kdr and uses thereof
|
|
US20030232437A1
(en)
|
2002-06-17 |
2003-12-18 |
Isis Pharmaceuticals Inc. |
Antisense modulation of VEGF-C expression
|
|
CA2494542A1
(en)
|
2002-05-03 |
2003-11-13 |
Ludwig Institute For Cancer Research |
Preventing secondary lymphedema with vegf-d dna
|
|
US20070184089A1
(en)
|
2002-07-15 |
2007-08-09 |
Alcon, Inc. |
Non-Polymeric Lipophilic Pharmaceutical Implant Compositions for Intraocular Use
|
|
AU2003252039A1
(en)
|
2002-07-23 |
2004-02-09 |
Vegenics Limited |
Methods and compositions for activating or inhibiting vegf-d and vegf-c
|
|
US20040023390A1
(en)
|
2002-08-05 |
2004-02-05 |
Davidson Beverly L. |
SiRNA-mediated gene silencing with viral vectors
|
|
WO2004020639A2
(en)
|
2002-08-14 |
2004-03-11 |
Avidis Sa |
Production of multimeric fusion proteins using a c4bp scaffold
|
|
EP1558278B1
(en)
|
2002-10-11 |
2009-09-02 |
ZymoGenetics, Inc. |
Production of homotrimeric fusion proteins
|
|
US20050048099A1
(en)
|
2003-01-09 |
2005-03-03 |
Allergan, Inc. |
Ocular implant made by a double extrusion process
|
|
CA2519835A1
(en)
|
2003-05-28 |
2004-12-09 |
Regeneron Pharmaceuticals, Inc. |
Method of treating corneal transplant rejection
|
|
US20050106667A1
(en)
|
2003-08-01 |
2005-05-19 |
Genentech, Inc |
Binding polypeptides with restricted diversity sequences
|
|
EP1732947B1
(en)
|
2004-03-05 |
2011-04-27 |
Vegenics Pty Ltd |
Growth factor binding constructs materials and methods
|
|
US20050244500A1
(en)
|
2004-04-30 |
2005-11-03 |
Allergan, Inc. |
Intravitreal implants in conjuction with photodynamic therapy to improve vision
|
|
US20050244471A1
(en)
|
2004-04-30 |
2005-11-03 |
Allergan, Inc. |
Estradiol derivative and estratopone containing sustained release intraocular implants and related methods
|
|
US8529927B2
(en)
|
2004-04-30 |
2013-09-10 |
Allergan, Inc. |
Alpha-2 agonist polymeric drug delivery systems
|
|
US20050244462A1
(en)
|
2004-04-30 |
2005-11-03 |
Allergan, Inc. |
Devices and methods for treating a mammalian eye
|
|
CA2567686A1
(en)
|
2004-06-10 |
2005-12-29 |
Regeneron Pharmaceuticals, Inc. |
Use of vegf inhibitors for the treatment of human cancer
|
|
US20060110364A1
(en)
*
|
2004-08-20 |
2006-05-25 |
Ludwig Institute For Cancer Research |
Vector-mediated delivery of polynucleotides encoding soluble VEGF receptors
|
|
US7303748B2
(en)
|
2005-02-02 |
2007-12-04 |
Regeneron Pharmaceuticals, Inc. |
Method of treating eye injury with local administration of a VEGF inhibitor
|
|
JP5737826B2
(ja)
|
2005-03-11 |
2015-06-17 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
Ｖｅｇｆの阻害による貧血の処置
|
|
WO2007096398A1
(en)
|
2006-02-22 |
2007-08-30 |
University Of Zurich |
Soluble receptors and methods for treating autoimmune or demyelinating diseases
|
|
CA2654510C
(en)
|
2006-06-16 |
2015-03-17 |
Regeneron Pharmaceuticals, Inc. |
Vegf antagonist formulations suitable for intravitreal administration
|
|
AR063619A1
(es)
|
2006-12-18 |
2009-02-04 |
Alcon Res Ltd |
Dispositivos y metodos para la administraicion de un farmaco oftalmico
|
|
JP2011500086A
(ja)
|
2007-10-22 |
2011-01-06 |
シェーリング コーポレイション |
完全ヒト抗ｖｅｇｆ抗体および使用方法
|
|
CA2705152C
(en)
|
2007-11-09 |
2016-10-11 |
Peregrine Pharmaceuticals, Inc. |
Anti-vegf antibody compositions and methods
|
|
US8234784B2
(en)
|
2008-02-13 |
2012-08-07 |
Younger Steven W |
Valve piston repositioning apparatus and method
|
|
KR101581244B1
(ko)
|
2008-03-26 |
2015-12-31 |
에피토믹스, 인코포레이티드 |
항―ｖｅｇｆ 항체
|
|
BRPI0914251B1
(pt)
|
2008-06-25 |
2022-07-19 |
Novartis Ag |
Imunoligante recombinante, seu fragmento de ligação ao antígeno, uso dos mesmos, e composição
|
|
KR20110112307A
(ko)
|
2008-11-25 |
2011-10-12 |
앨더 바이오파마슈티컬즈, 인코포레이티드 |
알부민을 상승시키고 및／또는 ｃｒｐ를 낮추는 ｉｌ６의 길항제
|
|
KR101093717B1
(ko)
|
2008-11-26 |
2011-12-19 |
한국생명공학연구원 |
Ｖｅｇｆ―특이적인 인간항체
|
|
EP3028707A1
(en)
|
2009-05-01 |
2016-06-08 |
Ophthotech Corporation |
Methods for treating or preventing ophthalmological diseases
|
|
ES2753135T3
(es)
*
|
2012-05-07 |
2020-04-07 |
Allergan Inc |
Método de tratamiento de DMAE en pacientes resistentes a terapia anti-VEGF
|
|
RS60026B1
(sr)
*
|
2013-02-18 |
2020-04-30 |
Vegenics Pty Ltd |
Molekuli koji vezuju ligande i njihove upotrebe
|
|
EP2994758B1
(en)
*
|
2013-05-08 |
2017-12-20 |
Opthea Limited |
Biomarkers for age-related macular degeneration (amd)
|